Pharvaris N.V. - Ordinary shares, par value Euro 0.12 per share (PHVS)

CUSIP: N69605108

Q1 2026 13F Holders as of 31 Mar 2026

Holder snapshot 6 signals
Share change
-229,999
SEC-reported price per share
$28.25
Number of holders
110
Value change
-$6,360,608
Number of buys
42
Number of sells
40
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
70,522,724

Security key

N69605108

Report period

Q1 2026

Institutions

110

Top holders

10

Ownership snapshot

Top reported holders of PHVS - Pharvaris N.V. - Ordinary shares, par value Euro 0.12 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
VIKING GLOBAL INVESTORS LP
Disclosed value leader
GENERAL ATLANTIC, L.P.
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G 13F 3/4/5 Lead comparable stake: 5.6% 13D/G row: VIKING GLOBAL INVESTORS LP Showing 1-6 of 15 holder rows.

Quick read

VIKING GLOBAL INVESTORS LP leads the comparable SEC ownership view at 5.6%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VIKING GLOBAL INVESTORS LP's linked filing trail.
Comparable ownership Top 5
VIKING GLOBAL INVESTORS LP 5.6%
Venrock Healthcare Capital Partne... 3.8%
Bain Capital Life Sciences Fund, ... 2.5%
Annick Deschoolmeester 0.13%
David P. Meeker 0.09%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
VIKING GLOBAL INVESTORS LP
13D/G 13F
Company
5.6%
$103,206,008
3,653,310 shares
$0 31 Mar 2026
Venrock Healthcare Capital Partners III, L.P.
13D/G
3.8%
$51,436,214
2,047,620 shares
$0 30 Jun 2025
Bain Capital Life Sciences Fund, L.P.
13D/G
2.5%
$41,020,425
1,640,817 shares
-$5,670,300 31 Dec 2025
Annick Deschoolmeester
3/4/5
Chief Human Resources Officer
0.13%
$2,313,825
92,553 shares
18 Mar 2026
David P. Meeker
3/4/5
Director
0.09%
$1,629,175
65,167 shares
18 Mar 2026
GENERAL ATLANTIC, L.P.
13F
Company
13F
11%
$222,867,243
8,031,252 shares
31 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
110
Shares
58,921,412
Rows available
110
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q3 2025 Across Filers

Q3 2025 holders
83
Q1 2026 holders
110
Holder diff
27
Investor Q3 2025 Shares Q1 2026 Shares Share Diff Share Chg % Q3 2025 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .